|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 17:09
|
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 The SPINRAZA European Union marketing authorization has been updated to include the high dose regimen. The new high dose regimen comprises a more rapid loading phase, two 50 mg loading doses administered 14 days apart and 28 mg maintenance dose injections every four months thereafter. Individuals transitioning from the 12 mg dose will receive one 50 mg dose in place of their next 12 mg dose, followed by 28 mg maintenance doses every four months thereafter. SPINRAZA is for intrathecal use by lumbar puncture by health care professionals experienced in performing lumbar punctures....
|
|
|
|
|
07.01.26 - 15:15
|
Analyst Expectations For Biogen′s Future (Benzinga)
|
|
|
Latest Ratings for BIIB
DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
read more...
|
|
|
05.01.26 - 13:00
|
Samsung Bioepis initiates Byooviz commercialisation in Europe (PBR)
|
|
|
The company has assumed commercial rights for Byooviz from Biogen, and the product will now be available as a Samsung Bioepis brand across several European countries as part
The post Samsung Bioepis initiates Byooviz commercialisation in Europe appeared first on Pharmaceutical Business review....
|
|
|
|
|
22.12.25 - 17:24
|
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in neurofilament, a marker of neurodegeneration, further validate the clinical results and demonstrate QALSODY's impact on the underlying biology of SOD1-ALS....
|
|
|
19.12.25 - 22:01
|
The Week Ahead (Dec. 22 to 28): China′s Top Legislators Meet; U.S. Tightens Biometric Entry Rules (Caixin)
|
|
|
Dec. 22 to 27: China's top legislature opens key year-end session
The Standing Committee of the 14th National People's Congress holds its session in Beijing to review draft laws including the environment code and revisions to the Foreign Trade Law. The agenda for China's top legislative body also covers the national development planning law and other legal updates.
Dec. 22: Nasdaq 100 rebalancing takes effect
The index's quarterly rebalance becomes effective, adding companies such as Alnylam Pharmaceuticals Inc. and Seagate Technology Holdings PLC. Removed constituents include Lululemon Athletica Inc. and Biogen Inc., reflecting shifts in market capitalization.
Dec. 22: Adora Cruises halts Japan trips
The Adora Magic City cruise ship cancels all call ports in Japan starting Dec.22, rerouting to South Korea amid rising bilateral tensions. The operator, Adora Cruises, becomes the first domestic cruise line to publicly halt Japan routes.
Dec. 22: Guangzhou-Zhanjiang high-speed rail line begins opera...
|
|
|
|
|
|
|
10.12.25 - 18:31
|
Biogen Aktie: Analystenwarnung! HSBC sieht Risiko für Gewinne (Aktiencheck)
|
|
|
London (www.aktiencheck.de) - Biogen-Aktienanalyse von HSBC:
Die Analysten von HSBC stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) von "hold" auf "reduce" herab und setzen ein Kursziel von 143 USD (zuvor: 144 USD).
Die Herabstufung sei darauf zurückzuführen, dass Biogens "angeschlagene" Multiple-Sklerose-Sparte das Wachstum in anderen Bereichen überwiege. [mehr]...
|
|
|
|
|
10.12.25 - 15:03
|
Great Point Partners Acquires a Majority Stake in Lenis Group, a Full-Service Specialty Pharmaceutical Commercialization and Distribution Partner (Business Wire)
|
|
|
Former CEO of Biogen, Michel Vounatsos, Appointed Board Chairman of Lenis
GREENWICH, Conn. & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Great Point Partners (“GPP” or “the Firm”), a Greenwich-based private investment firm focused exclusively on the healthcare industry, today announced that it has acquired a majority stake in Lenis Group (“Lenis” or “the Company”), a fast-growing Slovenian-based full-service regional commercialization and distribution partner for niche and specialty Rx medicines in Central and Eastern Europe (“CEE”).
Founded in 2008, Lenis has become a trusted partner to biotechnology and pharmaceutical companies across the highly complex but rapidly growing CEE region, covering the entire product lifecycle – from early access and pre-launch, through launch and growth, to mature lifecycle management.
The Company is recognized for its strong compliance culture, market access and reimbursement capabilities, regulatory expertise, and high-quality medical and marketing functio...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
